Carbapenem-resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure [PublishAheadOfPrint]

We reviewed 37 patients treated for bacteremia due to carbapenem-resistant Pseudomonas aeruginosa (CR-Pa). Although 65% of isolates were multiple-drug resistant, therapeutic options were available as all were susceptible to ≥1 antibiotic. Ninety-two percent of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 hours). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. Pitt bacteremia score (P=0.046) and delayed active therapy (P=0.027) were predictive of death and microbiologic failure, respectively.

http://ift.tt/2eHBFOe